Aprea Therapeutics, Inc. (APRE) (CIK 0001781983) (APRE)
Activity window: Oct. 25, 2025 to Oct. 24, 2026
Export this company’s current score, component values, matched signals, and scoring date as a one-row CSV snapshot.
The total combines correspondence volume, AI sentiment, matched keywords and signals, and a weighted 8-K adjustment, capped at 10.0. This is the 365-day v1 snapshot. Computed: Oct. 24, 2026. Latest filing activity: Apr. 27, 2026. These dates describe different events.
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Apr. 27, 2026 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Aprea Therapeutics, Inc. that it will not review their recently filed registration statement on Form S-3. The letter emphasizes that the responsibility… | Read Filing EDGAR |
| Apr. 27, 2026 | CORRESP | Neutral/Informational | Moderate | Aprea Therapeutics, Inc. has submitted a request to the SEC for the acceleration of the effective date of its Registration Statement on Form S-3. The company aims for the registra… | Read Filing EDGAR |
| Mar. 17, 2026 | CORRESP | Neutral/Informational | Moderate | Aprea Therapeutics, Inc. has submitted a request for the acceleration of the effective date of its Registration Statement on Form S-3, aiming for it to become effective by March 1… | Read Filing EDGAR |
| Mar. 16, 2026 | CORRESP | Neutral/Informational | Low | Aprea Therapeutics, Inc. submitted a response to the SEC's comment letter regarding their Registration Statement on Form S-3. The SEC noted that the registration statement was fil… | Read Filing EDGAR |
| Feb. 24, 2026 | UPLOAD | Concern from SEC | High | The SEC has conducted a limited review of Aprea Therapeutics' registration statement filed on February 20, 2026, and has raised a concern regarding the timeliness of the filing. T… | Read Filing EDGAR |
| Dec. 23, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Aprea Therapeutics, Inc. that they will not review the company's registration statement filed on December 19, 2025. The SEC has reminded the company th… | Read Filing EDGAR |
| Dec. 23, 2025 | CORRESP | Neutral/Informational | Moderate | Aprea Therapeutics, Inc. has submitted a request to the SEC for the acceleration of the effectiveness of their Registration Statement on Form S-3, which was filed on December 19, … | Read Filing EDGAR |